mifepristone has been researched along with Astrocytoma, Grade IV in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Camacho-Arroyo, I; Cruz-Burgos, JM; Del Moral-Morales, A; Martínez-Martínez, E; Rodríguez-Dorantes, M; Velázquez-Vázquez, DE | 1 |
| Check, JH; Cohen, R; Sarumi, M; Wilson, C | 1 |
| Ashton, K; Davis, CH; Dawson, T; Golash, A; Lea, R; Ramaswamy, R; Roberts, P | 1 |
3 other study(ies) available for mifepristone and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Expression analysis of progesterone‑regulated miRNAs in cells derived from human glioblastoma.
Topics: Cell Line, Tumor; Glioblastoma; Humans; MicroRNAs; Mifepristone; Progesterone; Receptors, Progesterone; Transcriptome | 2021 |
Evidence that Mifepristone, a progesterone receptor antagonist, can cross the blood brain barrier and provide palliative benefits for glioblastoma multiforme grade IV.
Topics: Adult; Antineoplastic Agents; Blood-Brain Barrier; Glioblastoma; Humans; Male; Mifepristone; Neoplasm Grading; Palliative Care | 2014 |
Study of effectiveness of mifepristone for glioma cell line growth suppression.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Glioblastoma; Humans; Mifepristone | 2012 |